Investments
805Funds
24Partners & Customers
4
Want to inform investors similar to Atlas Venture about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Expert Collections containing Atlas Venture
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Find Atlas Venture in 2 Expert Collections, including Synthetic Biology.
Synthetic Biology
382 items
CB Insights Healthcare Smart Money Investors - 2020
25 items
Track the world's top-performing VC investors in healthcare. Firms are presented in alphabetical order.
Latest Atlas Venture News
Mar 1, 2023
Chroma Medicine , a Cambridge, MA-based genomic medicine company, raised $135M in Series B funding. The round was led by GV, with participation from additional new investors ARCH Venture Partners, DCVC Bio, Mubadala Capital, Sixth Street, and all existing investors Alexandria Venture Investments, Atlas Venture, Casdin Capital, Cormorant Asset Management, Janus Henderson Investors, Newpath Partners, Omega Funds, Osage University Partners, Sofinnova Partners, T Rowe Price, and Wellington Management. The company intends to use the funds to progress its single-dose epigenetic editing therapies and support expansion of novel genetic medicine platform designed to enable precise gene regulation while preserving genomic integrity. Led by CEO Catherine Stehman-Breen, Chroma Medicine is a biotechnology company providing genomic medicines that harness the cells’ innate mechanism for gene regulation to precisely and durably silence, activate, and multiplex genes using a single platform, without changing the underlying DNA sequence. This approach enables the company to more effectively address a wide range of diseases and to target multiple pathways for complex diseases. FinSMEs 01/03/2023
Atlas Venture Investments
805 Investments
Atlas Venture has made 805 investments. Their latest investment was in Chroma Medicine as part of their Series B on March 3, 2023.

Atlas Venture Investments Activity

Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
3/1/2023 | Series B | Chroma Medicine | $135M | No | Alexandria Venture Investments, ARCH Venture Partners, Atlas Venture, Casdin Capital, Cormorant Asset Management, DCVC Bio, Google Ventures, Janus Henderson Investors, Mubadala Capital, Newpath Partners, Omega Funds, Osage University Partners, Sixth Street Partners, Sofinnova Partners, T. Rowe Price, and Wellington Management | 7 |
12/30/2022 | PIPE | Disc Medicine | $53.5M | No | 1 | |
12/23/2022 | Seed VC - II | Amagma Therapeutics | $10M | Yes | 1 | |
12/22/2022 | Series C - II | |||||
10/14/2022 | Series A |
Date | 3/1/2023 | 12/30/2022 | 12/23/2022 | 12/22/2022 | 10/14/2022 |
---|---|---|---|---|---|
Round | Series B | PIPE | Seed VC - II | Series C - II | Series A |
Company | Chroma Medicine | Disc Medicine | Amagma Therapeutics | ||
Amount | $135M | $53.5M | $10M | ||
New? | No | No | Yes | ||
Co-Investors | Alexandria Venture Investments, ARCH Venture Partners, Atlas Venture, Casdin Capital, Cormorant Asset Management, DCVC Bio, Google Ventures, Janus Henderson Investors, Mubadala Capital, Newpath Partners, Omega Funds, Osage University Partners, Sixth Street Partners, Sofinnova Partners, T. Rowe Price, and Wellington Management | ||||
Sources | 7 | 1 | 1 |
Atlas Venture Acquisitions
2 Acquisitions
Atlas Venture acquired 2 companies. Their latest acquisition was NovusPharma on September 20, 1999.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
---|---|---|---|---|---|---|
9/20/1999 | Convertible Note | Management Buyout | 1 | |||
5/27/1993 |
Date | 9/20/1999 | 5/27/1993 |
---|---|---|
Investment Stage | Convertible Note | |
Companies | ||
Valuation | ||
Total Funding | ||
Note | Management Buyout | |
Sources | 1 |
Atlas Venture Fund History
24 Fund Histories
Atlas Venture has 24 funds, including Atlas Venture Fund XIII.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
---|---|---|---|---|---|
3/3/2022 | Atlas Venture Fund XIII | $450M | 1 | ||
7/6/2020 | Accomplice Fortuity Pool | $110M | 1 | ||
6/5/2020 | Atlas Venture Fund XII | $400M | 2 | ||
5/6/2020 | Pride Fund | ||||
1/2/2019 | Atlas Venture Opportunity Fund I |
Closing Date | 3/3/2022 | 7/6/2020 | 6/5/2020 | 5/6/2020 | 1/2/2019 |
---|---|---|---|---|---|
Fund | Atlas Venture Fund XIII | Accomplice Fortuity Pool | Atlas Venture Fund XII | Pride Fund | Atlas Venture Opportunity Fund I |
Fund Type | |||||
Status | |||||
Amount | $450M | $110M | $400M | ||
Sources | 1 | 1 | 2 |
Atlas Venture Partners & Customers
4 Partners and customers
Atlas Venture has 4 strategic partners and customers. Atlas Venture recently partnered with AbCellera on August 8, 2022.
Date | Type | Business Partner | Country | News Snippet | Sources |
---|---|---|---|---|---|
8/3/2022 | Licensor | Canada | AbCellera and Atlas Venture to collaborate on new company for therapeutic antibody discovery AbCellera Biologics Inc. and Atlas Venture have announced a multi-target partnership to discover therapeutic antibodies for up to three drug targets that can be developed and commercialized by a stealth-stage Atlas-backed company . | 6 | |
11/18/2014 | Partner | ||||
3/17/2014 | Partner | ||||
12/15/2011 | Partner |
Date | 8/3/2022 | 11/18/2014 | 3/17/2014 | 12/15/2011 |
---|---|---|---|---|
Type | Licensor | Partner | Partner | Partner |
Business Partner | ||||
Country | Canada | |||
News Snippet | AbCellera and Atlas Venture to collaborate on new company for therapeutic antibody discovery AbCellera Biologics Inc. and Atlas Venture have announced a multi-target partnership to discover therapeutic antibodies for up to three drug targets that can be developed and commercialized by a stealth-stage Atlas-backed company . | |||
Sources | 6 |
Atlas Venture Team
24 Team Members
Atlas Venture has 24 team members, including , .
Name | Work History | Title | Status |
---|---|---|---|
Michiel de Haan | Founder | Current | |
Name | Michiel de Haan | ||||
---|---|---|---|---|---|
Work History | |||||
Title | Founder | ||||
Status | Current |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.